Log in to your Inderes Free account to see all free content on this page.

SyntheticMR

Be the first to follow this company

SyntheticMR is a technology company. The company operates in the development of analysis and imaging methods. The technology is mainly used for magnetic resonance imaging (MRI) in healthcare. The technology is based on a quantification-based method that intends to increase the efficiency and quality of current MRI tests. The company was established in 2007 and is based in Linköping.

ShowingAll content types

Regulatory press releaseyesterday

SyntheticMR AB: SyntheticMR publishes disclosure document regarding rights issue

Regulatory press release12/17/2024, 1:51 PM

Announcement from extra general meeting in SyntheticMR AB (publ)

Press release12/6/2024, 7:44 PM

SyntheticMR AB: SyntheticMR receives FDA 510(k) clearance for SyMRI 15

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account

Stock market's most popular morning newsletter

Analyst comments and recommendations

Stock comparison tool

PREMIUM account

All company reports and content

Premium tools (e.g. insider transactions & stock screener)

Model portfolio

Regulatory press release12/4/2024, 3:23 PM

SyntheticMR AB (publ) appoints Vedran Beglerbegovic as Acting CEO for SyntheticMR

Regulatory press release11/28/2024, 10:10 PM

Notice of extra general meeting in SyntheticMR AB (publ)

Regulatory press release11/28/2024, 10:05 PM

SyntheticMR AB: SyntheticMR resolves on a rights issue of approximately SEK 65 million

Regulatory press release11/28/2024, 9:55 PM

SyntheticMR AB: SyntheticMR signs agreement to acquire Finnish Combinostics Oy

Press release11/22/2024, 2:00 PM

SyntheticMR AB: Nomination Committee appointed for the 2025 Annual General Meeting in SyntheticMR

Regulatory press release11/18/2024, 7:14 AM

SyntheticMR AB: Interim report July - September 2024

Regulatory press release11/6/2024, 5:52 PM

SyntheticMR AB (publ) brings forward the publication date of the interim report for the period 1 January - 30 September 2024 to Monday, 18 November 2024.

Press release10/29/2024, 10:27 AM

SyntheticMR AB: SyntheticMR Receives Regulatory Approval for SyMRI 15 in Australia

Press release10/2/2024, 8:15 AM

SyntheticMR AB: SyntheticMR Receives Regulatory Approval for SyMRI 15 in Switzerland

Press release9/25/2024, 8:00 AM

SyntheticMR AB: SyntheticMR Announces Regulatory Clearance for SyMRI 15 in the UK

Press release9/4/2024, 8:00 AM

SyntheticMR AB: SyntheticMR Announces the Appointment of Francois Hebert as New President, North America

Regulatory press release8/27/2024, 6:49 AM

SyntheticMR AB: Interim report April - June 2024

Press release8/19/2024, 8:48 AM

SyntheticMR AB: SyntheticMR Receives Regulatory Approval for SyMRI in Taiwan

Regulatory press release7/9/2024, 7:34 PM

SyntheticMR AB: SyntheticMR announces estimated net sales of SEK 12m. (21.2) for quarter 2 of 2024 depending on organizational changes in USA. The net sales target for 2024 is therefore not expected to be achieved

Regulatory press release6/26/2024, 11:30 AM

SyntheticMR AB: SyMRI 15 by SyntheticMR obtains CE-Marking

Regulatory press release5/22/2024, 6:22 AM

Report from Annual General Meeting in SyntheticMR AB (publ)

Regulatory press release5/21/2024, 6:08 AM

SyntheticMR AB: Interim report January - March 2024

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.